Patients are being overtreated with cancer drugs, as evidence suggests lower doses are often just as effective with fewer side effects.
A study estimated $31 billion could have been saved in 2024 alone through dose optimization, but financial incentives for drugmakers and hospitals block this research.
The FDA’s “Project Optimus” promotes lower-dose studies, but the agency lacks legal power to force drugmakers to test reduced dosages post-approval.
Fewer than half of cancer drugs approved since 2000 have proven to extend survival, while the median price has quadrupled to $25,000 per month.
Patient advocates demand informed consent, arguing people deserve plain facts about a drug’s true benefits and costs before risking their savings and health.
Why are cancer patients being prescribed FDA-approved doses that may be far higher than necessary? A recent investigation by KFF Health News highlights a growing movement of researchers and doctors challenging standard dosing protocols for expensive immunotherapies and other cancer drugs. Their work suggests many patients could receive lower or less frequent doses, reducing side effects and saving billions in healthcare costs without compromising outcomes. Oncologists worldwide are finding that less can be more, raising questions about the financial incentives baked into current prescribing practices.
Read Full Article: https://www.naturalnews.com/2026-08-21-high-cancer-drug-doses-lower-amounts-effective.html
